Men with locally advanced prostate cancer have a better survival chance if they receive radiotherapy along with androgen deprivation therapy (ADT). This data was presented at the recent American Society of Clinical Oncology (ASCO) 2012 conference. Professor Malcom Mason from Whales University discussed a trial he conducted that demonstrated that for a man diagnosed with [...]
Science and good medicine is not always what it seems. We all believe that if something is logical it must be true, but often the most logical assumptions we make do not stand up to good scientific inquiry. Many of us choke on the fact that Provenge extends life while it has no effect on [...]
In a study conducted by Choueiri et al. published in Cancer it was suggested that men who have prostate cancer that was treated by a radical prostatectomy (RP) who then had a long time to a biochemical recurrence (BCR) or a long PSA doubling time after a BCR have no higher overall risk of death [...]
According to an article published in URO Today the belief that adjuvant androgen suppression therapy (AST) is associated with early deaths due to myocardial infarctions (MCIs) is not true. The belief that ASTs increases deaths from MCIs comes from the TROG 96.01 trial conclusions. Now there has been a retrospective, long term (ten year) meta-analysis [...]
One of the more common myths about hormone therapy (ADT) to treat prostate cancer is that its effectiveness will last only for one and a half to two years. For some men this might be true, but it is not a reality in today’s prostate cancer landscape. What makes this myth worse is that it [...]